Cullinan Therapeutics Inc. (CGEM) Live Share Price, Invest From India

Cullinan Therapeutics Inc. Stock Performance

as on June 18, 2026 at 2:15 pm IST

Day's Low
Day's High
$13.63
Day's Price Range
$15.25
$14.44
5.61%
Downside
5.61%
Upside
52 Week's Low
52 Week's High
$5.68
52-Week Price Range
$16.74
$14.44
60.66%
Downside
15.93%
Upside

Cullinan Therapeutics Inc. share price movements today

Previous Close: $13.55
Open: $13.64
Volume: 1.9M
Day's Low - High: $13.63 - $15.25
52 Week Low - High: $5.68 - $16.74

Cullinan Therapeutics Inc. Historical Returns

1 Month Return: -2.89 %
3 Month Return: + 9.98 %
1 Year Return: + 76.96 %
3 Year Return: + 10.65 %
5 Year Return: -43.24 %

Cullinan Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Cullinan Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$919.4M

EPS (TTM)

-2.9981

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-240.0M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-48.16%

Cullinan Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Cullinan Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Cullinan Therapeutics Inc.	BUY	$919.4M	-43.24%	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$37.6B	59.83%	71.01	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$115.0B	144.34%	26.88	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$64.4B	13.01%	15.02	29.65%	0.58%

Stock Returns calculator for Cullinan Therapeutics Inc. Stock including INR - Dollar returns

The Cullinan Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Cullinan Therapeutics Inc. investment value today

Current value as on today

₹1,93,736

Returns

₹93,736

(+93.74%)

Returns from Cullinan Therapeutics Inc. Stock

₹76,961 (+76.96%)

Dollar Impact

₹16,775 (+16.78%)

Analyst Recommendation on Cullinan Therapeutics Inc. Stock

Based on 14 analysts

BUY

92.86%

Buy

7.14%

Hold

0.00%

Sell

Based on 14 analysts, 92.86% of analysts recommend a 'BUY' rating for Cullinan Therapeutics Inc.. Average target price of $31.55

Cullinan Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Cullinan Therapeutics Inc..

What analysts predicted

54.23%UPSIDE

Target Price

$31.55

Current Price

$14.44

Analyzed by

14 Analysts

Target

$31.55

Cullinan Therapeutics Inc. target price $31.55, a slight upside of 54.23% compared to current price of $14.44. According to 14 analysts rating.

Cullinan Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit	0	0	0	0	0	0	0	-	0	0
Operating Income	-45	-42	-50	-48	-55	-54	-75	-55	-55	-53
EBITDA	-39	-37	-41	-40	-47	-48	-69	-50	-50	-49
Interest Expense	-	-	-	-	-	-	-	-	-	-
Depreciation	0	0	0	0	0	0	0	0	0	0
Income Before Tax	-39	-37	-42	-40	-47	-48	-70	-50	-50	-49
Income Tax Expense	-14	0	-	-	0	-	-	-	-	-
Net Income	-23	-37	-42	-40	-47	-48	-70	-50	-50	-49
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Cullinan Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	-	-	18	18	-	-	-	-
Gross Profit	-	-	0	0	0	18	0	0	0	0
Operating Income	0	0	-14	-22	-60	-67	144	-191	-196	-241
EBITDA	-	-	-14	-22	-60	-67	-132	-190	-167	-219
Interest Expense	-	-	-	-	0	65	562	-	-	-
Depreciation	-	-	0	0	0	0	0	0	0	0
Income Before Tax	0	0	-14	-21	-59	-67	151	-169	-167	-219
Income Tax Expense	-	-	0	-1	-8	-2	42	-14	0	-
Net Income	0	0	-14	-20	-50	-65	111	-153	-167	-219
Net Profit Margin	0.00%	0.00%	0.00%	0.00%	-268.43%	-343.35%	0.00%	0.00%	0.00%	0.00%

Cullinan Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-37	-42	-40	-47	-48	-70	-50	-50	-49
Operating Cash Flow	-38	-36	-34	-36	-43	-57	-36	-38	-46
Investing Cash Flow	12	-185	19	15	36	53	67	22	32
Financing Cash Flow	1	262	1	1	-	0	-	0	0
Change in Cash	-24	40	-12	-19	-6	-3	30	-15	-13

Cullinan Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	0	-14	-20	-51	-67	109	-153	-167	-219
Operating Cash Flow	0	-13	-20	-29	-43	-126	-134	-145	-175
Investing Cash Flow	-	0	-35	-5	-333	248	35	-136	179
Financing Cash Flow	0	0	85	140	268	-25	40	266	1
Change in Cash	0	-13	29	104	-108	96	-57	-15	5

Global Institutional Holdings in Cullinan Therapeutics Inc.

Funds	Holdings
Kynam Capital Management, LP	5.07%
Patient Square Capital	1.47%
BOOTHBAY FUND MANAGEMENT, LLC	1.81%
The Goldman Sachs Group Inc	1.17%
Lynx1 Capital Management, LP	14.58%

See all

Insights on Cullinan Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 7 days, CGEM stock has moved up by 11.2%
POSITIVE IMPACT
Best in 1 Year
In the last 1 year, CGEM has outperformed top 5 stocks with highest market-cap in its industry
POSITIVE IMPACT
Best in 3 Years
In the last 3 years, CGEM has outperformed top 5 stocks with highest market-cap in its industry

About Cullinan Therapeutics Inc.

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Organisation	Cullinan Therapeutics Inc.
Headquarters	One Main Street, Cambridge, MA, United States, 02142
Industry	Biotechnology
CEO	Mr. Nadim Ahmed M.S.
E-voting on shares	Click here to vote

Key Management of Cullinan Therapeutics Inc.

Name	Title
Mr. Nadim Ahmed M.S.	President, CEO & Director
Dr. Jeffrey Jones M.B.A., M.D., M.P.H.	Chief Medical Officer
Nicholas Smith	Head of Investor Relations
Ms. Jacquelyn L. Sumer J.D.	Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
Ms. Mary Kay Fenton CPA	Chief Financial Officer
Dr. Patrick A. Baeuerle Ph.D.	Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
Dr. Jennifer Michaelson Ph.D.	Chief Scientific Officer
Mr. Steve Andre	Chief Human Resources Officer
Dr. Corinne Savill Ph.D.	Chief Business Officer
Ms. Rose Weldon	Senior Vice President of Corporate Affairs

FAQs

What is Cullinan Therapeutics Inc. share price today?

Cullinan Therapeutics Inc. share price today is $14.44 as on June 18, 2026 at 8:45 am IST at the close of the market. Cullinan Therapeutics Inc. share today touched a day high of $15.25 and a low of $13.63.

What is the 52 week high and 52 week low for Cullinan Therapeutics Inc. share?

Cullinan Therapeutics Inc. share touched a 52 week high of $16.74 on February 27, 2026 and a 52 week low of $5.68 on October 3, 2025. Cullinan Therapeutics Inc. stock price today i.e. June 18, 2026 at 8:45 am IST is closed at $14.44,which is 13.74% down from its 52 week high and 154.23% up from its 52 week low.

What is Cullinan Therapeutics Inc.'s market capitalisation today?

Cullinan Therapeutics Inc. market capitalisation is $0.00T as on June 18, 2026 at 8:45 am IST.

How to invest in Cullinan Therapeutics Inc. Stock (CGEM) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Cullinan Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Cullinan Therapeutics Inc. Shares that will get you 0.1039 shares as per Cullinan Therapeutics Inc. share price of $14.44 per share as on June 18, 2026 at 8:45 am IST.

What is the minimum amount required to buy Cullinan Therapeutics Inc. Stock (CGEM) from India?

Indian investors can start investing in Cullinan Therapeutics Inc. (CGEM) shares with as little as ₹94.5 or $1 (as of June 18, 2026 at 4:05 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹945.00 in Cullinan Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on June 18, 2026 at 4:05 pm IST). Based on Cullinan Therapeutics Inc. share’s latest price of $14.44 as on June 18, 2026 at 8:45 am IST, you will get 0.6925 shares of Cullinan Therapeutics Inc.. Learn more about fractional shares .

What are the returns that Cullinan Therapeutics Inc. has given to Indian investors in the last 5 years?

Cullinan Therapeutics Inc. stock has given -43.24% share price returns and 27.67% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?